Related content

Phase 2 Trial of Moderately High Dose Single Agent Mitoxantrone in Platinum and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Lichtman S.M.   Homesley H.   Kennedy A.   Webster K.   Ernst S.   Omura G.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 1, 1998-07 ,pp. : 123-126

Elsevier

Access to resources Recommend Favorite

Phase 2 Trial of Liposomal Doxorubicin (40 mg/m 2 ) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum

By Markman M.   Kennedy A.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 78, Iss. 3, 2000-09 ,pp. : 369-372

Elsevier

Access to resources Recommend Favorite

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

By Markman M.   Webster K.   Zanotti K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 593-596

Elsevier

Access to resources Recommend Favorite

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite